353 related articles for article (PubMed ID: 15623630)
1. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.
Yang Q; Zage P; Kagan D; Tian Y; Seshadri R; Salwen HR; Liu S; Chlenski A; Cohn SL
Clin Cancer Res; 2004 Dec; 10(24):8493-500. PubMed ID: 15623630
[TBL] [Abstract][Full Text] [Related]
2. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines.
Harada K; Toyooka S; Maitra A; Maruyama R; Toyooka KO; Timmons CF; Tomlinson GE; Mastrangelo D; Hay RJ; Minna JD; Gazdar AF
Oncogene; 2002 Jun; 21(27):4345-9. PubMed ID: 12082624
[TBL] [Abstract][Full Text] [Related]
3. Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome.
Yang Q; Kiernan CM; Tian Y; Salwen HR; Chlenski A; Brumback BA; London WB; Cohn SL
Clin Cancer Res; 2007 Jun; 13(11):3191-7. PubMed ID: 17545522
[TBL] [Abstract][Full Text] [Related]
4. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
[TBL] [Abstract][Full Text] [Related]
5. Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours.
Honorio S; Agathanggelou A; Wernert N; Rothe M; Maher ER; Latif F
Oncogene; 2003 Jan; 22(3):461-6. PubMed ID: 12545168
[TBL] [Abstract][Full Text] [Related]
6. Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma.
Lázcoz P; Muñoz J; Nistal M; Pestaña A; Encío I; Castresana JS
BMC Cancer; 2006 Oct; 6():254. PubMed ID: 17064406
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers.
Agathanggelou A; Dallol A; Zöchbauer-Müller S; Morrissey C; Honorio S; Hesson L; Martinsson T; Fong KM; Kuo MJ; Yuen PW; Maher ER; Minna JD; Latif F
Oncogene; 2003 Mar; 22(10):1580-8. PubMed ID: 12629521
[TBL] [Abstract][Full Text] [Related]
8. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
Lee MG; Kim HY; Byun DS; Lee SJ; Lee CH; Kim JI; Chang SG; Chi SG
Cancer Res; 2001 Sep; 61(18):6688-92. PubMed ID: 11559536
[TBL] [Abstract][Full Text] [Related]
9. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma.
Byun DS; Lee MG; Chae KS; Ryu BG; Chi SG
Cancer Res; 2001 Oct; 61(19):7034-8. PubMed ID: 11585730
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic inactivation of RASSF1a in uveal melanoma.
Maat W; van der Velden PA; Out-Luiting C; Plug M; Dirks-Mulder A; Jager MJ; Gruis NA
Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):486-90. PubMed ID: 17251440
[TBL] [Abstract][Full Text] [Related]
11. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of RAS association domain family 1A gene in cervical carcinomas and the role of human papillomavirus infection.
Kuzmin I; Liu L; Dammann R; Geil L; Stanbridge EJ; Wilczynski SP; Lerman MI; Pfeifer GP
Cancer Res; 2003 Apr; 63(8):1888-93. PubMed ID: 12702579
[TBL] [Abstract][Full Text] [Related]
13. Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma.
Murray PG; Qiu GH; Fu L; Waites ER; Srivastava G; Heys D; Agathanggelou A; Latif F; Grundy RG; Mann JR; Starczynski J; Crocker J; Parkes SE; Ambinder RF; Young LS; Tao Q
Oncogene; 2004 Feb; 23(6):1326-31. PubMed ID: 14961078
[TBL] [Abstract][Full Text] [Related]
14. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.
Astuti D; Agathanggelou A; Honorio S; Dallol A; Martinsson T; Kogner P; Cummins C; Neumann HP; Voutilainen R; Dahia P; Eng C; Maher ER; Latif F
Oncogene; 2001 Nov; 20(51):7573-7. PubMed ID: 11709729
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.
Tomizawa Y; Kohno T; Kondo H; Otsuka A; Nishioka M; Niki T; Yamada T; Maeshima A; Yoshimura K; Saito R; Minna JD; Yokota J
Clin Cancer Res; 2002 Jul; 8(7):2362-8. PubMed ID: 12114441
[TBL] [Abstract][Full Text] [Related]
16. Promoter hypermethylation of RASSF1A in esophageal squamous cell carcinoma.
Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Mori M; Croce CM
Clin Cancer Res; 2003 Apr; 9(4):1441-5. PubMed ID: 12684417
[TBL] [Abstract][Full Text] [Related]
17. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance.
Lee ES; Issa JP; Roberts DB; Williams MD; Weber RS; Kies MS; El-Naggar AK
Clin Cancer Res; 2008 May; 14(9):2664-72. PubMed ID: 18451230
[TBL] [Abstract][Full Text] [Related]
18. Patterns of gene promoter methylation in squamous cell cancer of the head and neck.
Hasegawa M; Nelson HH; Peters E; Ringstrom E; Posner M; Kelsey KT
Oncogene; 2002 Jun; 21(27):4231-6. PubMed ID: 12082610
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
Spugnardi M; Tommasi S; Dammann R; Pfeifer GP; Hoon DS
Cancer Res; 2003 Apr; 63(7):1639-43. PubMed ID: 12670917
[TBL] [Abstract][Full Text] [Related]
20. Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma.
Fischer JR; Ohnmacht U; Rieger N; Zemaitis M; Stoffregen C; Kostrzewa M; Buchholz E; Manegold C; Lahm H
Lung Cancer; 2006 Oct; 54(1):109-16. PubMed ID: 16893590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
